Overview

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB
Phase:
Phase 4
Details
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Treatments:
Mandelic Acids
Muscarinic Antagonists
Oxybutynin
Tolterodine Tartrate